SG11201504380SA - Method for treatment of diseases - Google Patents
Method for treatment of diseasesInfo
- Publication number
- SG11201504380SA SG11201504380SA SG11201504380SA SG11201504380SA SG11201504380SA SG 11201504380S A SG11201504380S A SG 11201504380SA SG 11201504380S A SG11201504380S A SG 11201504380SA SG 11201504380S A SG11201504380S A SG 11201504380SA SG 11201504380S A SG11201504380S A SG 11201504380SA
- Authority
- SG
- Singapore
- Prior art keywords
- diseases
- treatment
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/58—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4836—Diagnosis combined with treatment in closed-loop systems or methods
- A61B5/4839—Diagnosis combined with treatment in closed-loop systems or methods combined with drug delivery
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61B—DIAGNOSIS; SURGERY; IDENTIFICATION
- A61B5/00—Measuring for diagnostic purposes; Identification of persons
- A61B5/48—Other medical applications
- A61B5/4869—Determining body composition
- A61B5/4872—Body fat
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/10—Antioedematous agents; Diuretics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/14—Vasoprotectives; Antihaemorrhoidals; Drugs for varicose therapy; Capillary stabilisers
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Heart & Thoracic Surgery (AREA)
- Diabetes (AREA)
- Cardiology (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Hematology (AREA)
- Surgery (AREA)
- Molecular Biology (AREA)
- Medical Informatics (AREA)
- Biophysics (AREA)
- Pathology (AREA)
- Physics & Mathematics (AREA)
- Vascular Medicine (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Pulmonology (AREA)
- Ophthalmology & Optometry (AREA)
- Endocrinology (AREA)
- Emergency Medicine (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201261739524P | 2012-12-19 | 2012-12-19 | |
PCT/US2013/076421 WO2014100352A1 (fr) | 2012-12-19 | 2013-12-19 | Méthode de traitement de maladies |
Publications (1)
Publication Number | Publication Date |
---|---|
SG11201504380SA true SG11201504380SA (en) | 2015-07-30 |
Family
ID=50979197
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201504380SA SG11201504380SA (en) | 2012-12-19 | 2013-12-19 | Method for treatment of diseases |
SG10201705044YA SG10201705044YA (en) | 2012-12-19 | 2013-12-19 | Method for treatment of diseases |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201705044YA SG10201705044YA (en) | 2012-12-19 | 2013-12-19 | Method for treatment of diseases |
Country Status (15)
Country | Link |
---|---|
US (2) | US9351979B2 (fr) |
EP (1) | EP2934546A4 (fr) |
JP (1) | JP2016503794A (fr) |
KR (1) | KR20150105355A (fr) |
CN (1) | CN104968350A (fr) |
AU (1) | AU2013361338A1 (fr) |
BR (1) | BR112015014261A8 (fr) |
CA (1) | CA2895340A1 (fr) |
EA (1) | EA201500752A1 (fr) |
HK (1) | HK1216504A1 (fr) |
IL (1) | IL239273A0 (fr) |
MX (1) | MX2015007845A (fr) |
PH (1) | PH12015501561A1 (fr) |
SG (2) | SG11201504380SA (fr) |
WO (1) | WO2014100352A1 (fr) |
Families Citing this family (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
HUE028212T2 (en) | 2009-06-22 | 2016-12-28 | Ampio Pharmaceuticals Inc | Procedure for treating diseases |
US9532866B2 (en) * | 2012-03-15 | 2017-01-03 | L&C Bio Co., Ltd. | Acellular dermal graft |
AU2013361338A1 (en) * | 2012-12-19 | 2015-08-06 | Ampio Pharmaceuticals, Inc. | Method for treatment of diseases |
KR102218042B1 (ko) * | 2016-10-17 | 2021-02-18 | 각고호우징 게이오기주크 | 미분화 줄기세포 제거제, 및 미분화 줄기세포 제거 방법 |
US20210177751A1 (en) * | 2017-12-08 | 2021-06-17 | The Johns Hopkins University | Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces |
Family Cites Families (101)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
NL241544A (fr) | 1958-07-23 | |||
US3135743A (en) | 1960-06-29 | 1964-06-02 | Sterling Drug Inc | Steroido[2. 3-d]isoxazoles and preparation thereof |
GB1123770A (en) | 1966-11-15 | 1968-08-14 | Sterling Drug Inc | 2-cyano-3-oxo-steroids |
US4160027A (en) | 1977-12-20 | 1979-07-03 | Sterling Drug Inc. | Steroid cyanoketones and intermediates |
US4994443A (en) | 1982-12-20 | 1991-02-19 | The Children's Medical Center Corporation | Inhibition of angiogenesis |
US5714481A (en) | 1983-08-02 | 1998-02-03 | Research Corporation Technologies, Inc. | Derivatives of 5-androsten-17 ones and 5-androstan-17-ones |
US4617299A (en) | 1983-12-19 | 1986-10-14 | Knepper Paul A | Method for the prevention of ocular hypertension, treatment of glaucoma and treatment of ocular hypertension |
US4837212A (en) | 1984-11-15 | 1989-06-06 | University Of Miami | Treatment of hemolytic anemia with danazol |
US4975537A (en) | 1985-10-23 | 1990-12-04 | The Upjohn Company | Δ9(11) -angiostatic steroids |
EP0244178A3 (fr) | 1986-04-28 | 1989-02-08 | Iolab, Inc | Compositions intraoculaires et leur procédé d'utilisation |
DE3738620A1 (de) | 1987-11-13 | 1989-05-24 | Luderschmidt Christoph | Verwendung von ethisterone zur topischen behandlung von akne oder androgenetischer alopezie |
US5407926A (en) | 1987-12-29 | 1995-04-18 | Alcon Laboratories, Inc. | Ophthalmic composition |
JP2680614B2 (ja) | 1988-08-01 | 1997-11-19 | 日清製粉株式会社 | ダナゾール組成物 |
US5990099A (en) | 1988-10-31 | 1999-11-23 | Alcon Laboratories, Inc. | Angiostatic agents and methods and compositions for controlling ocular hypertension |
US5372996A (en) | 1989-03-10 | 1994-12-13 | Endorecherche, Inc. | Method of treatment of androgen-related diseases |
ES2121570T3 (es) | 1989-07-07 | 1998-12-01 | Endorecherche Inc | Derivados de androgenos para uso en la inhibicion de la actividad de los esteroides sexuales. |
US5972922A (en) | 1990-06-11 | 1999-10-26 | Alcon Laboratories, Inc. | Steroids which inhibit angiogenesis |
ATE190623T1 (de) | 1990-06-11 | 2000-04-15 | Alcon Lab Inc | Verwendung von steroiden zur inhibierung von angiogenesis |
JPH04149132A (ja) | 1990-10-13 | 1992-05-22 | Bairon Boeki Kk | ダナゾール水溶液 |
JPH0735335B2 (ja) | 1991-02-28 | 1995-04-19 | 五十嵐 正雄 | 子宮内膜症の治療薬 |
CA2111699A1 (fr) | 1991-06-18 | 1992-12-23 | Gerard Schwadrohn | Compositions pharmaceutiques anti-glaucomateuses et leur procede d'obtention |
ATE232540T1 (de) | 1991-11-22 | 2003-02-15 | Alcon Lab Inc | Angiostatische steroide |
US5679666A (en) | 1991-11-22 | 1997-10-21 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization by treatment with angiostatic steroids |
US5770592A (en) | 1991-11-22 | 1998-06-23 | Alcon Laboratories, Inc. | Prevention and treatment of ocular neovascularization using angiostatic steroids |
GB9200210D0 (en) | 1992-01-07 | 1992-02-26 | British Bio Technology | Compounds |
ATE185697T1 (de) | 1992-04-21 | 1999-11-15 | Schepens Eye Res Inst | Androgentherapie am auge beim sjögrensyndrom |
ES2068742B1 (es) | 1993-02-11 | 1995-11-16 | Uriach & Cia Sa J | Nuevos derivados de piridinio. |
US5770589A (en) | 1993-07-27 | 1998-06-23 | The University Of Sydney | Treatment of macular degeneration |
US5646136A (en) | 1994-01-04 | 1997-07-08 | Duke University | Methods of inhibiting angiogenesis and tumor growth, and treating ophthalmologic conditions with angiostatic and therapeutic steroids |
NZ283658A (en) | 1994-04-04 | 1999-09-29 | William R Freeman | Compositions and treatment of increased intraocular pressure with phosphonyl-alkyloxy-pyrimidines/purines (nucleosides) |
US5885591A (en) | 1996-07-02 | 1999-03-23 | Johnson & Johnson Consumer Products, Inc. | Personal lubricant compositions |
US5929111A (en) | 1996-12-18 | 1999-07-27 | Alcon Laboratories, Inc. | A-seco steroids effective at treating ophthalmic pathological neovascularization and controlling intraocular pressure |
US5993856A (en) | 1997-01-24 | 1999-11-30 | Femmepharma | Pharmaceutical preparations and methods for their administration |
WO1998043647A1 (fr) | 1997-03-28 | 1998-10-08 | Massachusetts Institute Of Technology, Inc. | Regulation de l'expression de la proteine precurseur amyloide (app) au moyen de composes oestrogeniques |
US6011023A (en) | 1997-08-27 | 2000-01-04 | Alcon Laboratories, Inc. | Angiostatic steroids |
US6054446A (en) | 1997-12-24 | 2000-04-25 | Sri International | Anti-estrogenic steroids, and associated pharmaceutical compositions and methods of use |
EP0939124A3 (fr) | 1998-02-24 | 2001-03-21 | Smithkline Beecham Plc | Séquences de la MBGP1 |
GB9807809D0 (en) | 1998-04-09 | 1998-06-10 | Multimed Ltd | Compositions comprising ethisterone or its derivatives |
US6645954B2 (en) | 1998-04-09 | 2003-11-11 | Multimed Limited | Compositions comprising ethisterone or its derivatives |
CA2336703A1 (fr) | 1998-07-10 | 2000-01-20 | The University Of Sydney | Traitements prophylactiques de la neoformation de vaisseaux sanguins dans la degenerescence maculaire |
US20040063719A1 (en) | 1998-08-26 | 2004-04-01 | Queen's University At Kingston | Combination therapy using antihypertensive agents and endothelin antagonists |
EP1022027A1 (fr) | 1999-01-22 | 2000-07-26 | Applied Research Systems ARS Holding N.V. | Antagonistes du TNF (Tumor necrosis factor) et leurs utilisations contre l'endometriose |
EP1074634B1 (fr) | 1999-07-09 | 2002-10-02 | Institut Pasteur De Lille | Procédé pour le diagnostic ou le prognostic de la maladie d'Alzheimer: Composition therapeutique pour la prévention ou le traitement de la maladie d'Alzheimer |
US6610674B1 (en) | 1999-09-28 | 2003-08-26 | University Of Pennsylvania | Method of treating inflammatory conditions with progesterone analogs |
BR0014929B1 (pt) | 1999-10-21 | 2009-01-13 | dispositivo para distribuiÇço de medicamento oftÁlmico. | |
EP1225879A2 (fr) | 1999-10-22 | 2002-07-31 | Orbon Corporation | Traitement topique de l'hypertension oculaire, du glaucome, de la retinopathie ischemique et de la degenerescence maculaire liee a l'age par une formulation ophtalmique d'antagonistes de la dopamine |
US6562369B2 (en) | 1999-12-16 | 2003-05-13 | Dermatrends, Inc. | Transdermal administration of androgenic drugs hydroxide-releasing agents as permeation enhancers |
WO2001051494A1 (fr) | 2000-01-12 | 2001-07-19 | Merck & Co., Inc. | Inhibiteurs de prenyle-proteine transferase |
GB2345851B (en) | 2000-01-18 | 2004-05-26 | Gavin Paul Vinson | A combination of trilostane or keto-trilostane and an anti-oestrogen for the treatment of an oestrogen-dependent cancer or tumour |
US20020055512A1 (en) | 2000-01-21 | 2002-05-09 | Cortendo Ab. | Compositions for delivery of a cortisol antagonist |
JP2003529567A (ja) | 2000-03-10 | 2003-10-07 | インサイト・ビジョン・インコーポレイテッド | 後眼部眼疾患を治療および予防する方法と組成物 |
BR0112969A (pt) | 2000-08-04 | 2004-06-22 | Dmi Biosciences Inc | Método de utilização de dicetopiperazinas e composições contendo-as |
US20040082557A1 (en) | 2001-01-26 | 2004-04-29 | Wajszczuk Charles Paul | Methods for treating estrogen-dependent disorders |
JP2004537506A (ja) | 2001-03-01 | 2004-12-16 | ホリス − イーデン ファーマスーティカルズ、 インコーポレイテッド | 血液細胞欠乏症を治療するためのある種のステロイドの使用 |
GB2375958B (en) | 2001-04-09 | 2005-03-02 | George Margetts | The use of steroids to lower the levels of cortisol |
US6936599B2 (en) | 2001-04-25 | 2005-08-30 | The Regents Of The University Of California | Estriol therapy for multiple sclerosis and other autoimmune diseases |
WO2002087543A1 (fr) | 2001-05-01 | 2002-11-07 | Biozone Laboratories, Inc. | Preparations a liberation prolongee de nifedipine, de dextromethorphane et de danazol |
AU2002344237B8 (en) | 2001-05-29 | 2008-11-06 | Sirna Therapeutics, Inc. | Nucleic Acid Based Modulation of Female Reproductive Diseases and Conditions |
FR2825277B1 (fr) | 2001-05-30 | 2004-10-15 | Oreal | Composition cosmetique et/ou dermatologique et/ou pharmaceutique contenant au moins un compose ihnibiteur de l'enzime 3, b-hsd |
US20030050291A1 (en) | 2001-06-12 | 2003-03-13 | Yadon Arad | Adrenal enzyme inhibitors |
US20030232798A1 (en) | 2001-06-12 | 2003-12-18 | Yadon Arad | Adrenal enzyme inhibitors |
US20040219208A1 (en) | 2001-08-03 | 2004-11-04 | Ryu Kawamura | Sustained-release medicines |
EP1494699A4 (fr) | 2002-04-11 | 2009-07-22 | Childrens Medical Center | Methodes permettant d'inhiber l'hyperpermeabilite vasculaire |
EP1539183A4 (fr) | 2002-08-28 | 2007-04-25 | Hollis Eden Pharmaceuticals | Procedes de traitement therapeutique |
US7354574B2 (en) | 2002-11-07 | 2008-04-08 | Advanced Ocular Systems Limited | Treatment of ocular disease |
DE60305068T2 (de) | 2002-12-18 | 2007-01-11 | Laboratoires Besins International | Behandlung von mastalgie mit 4-hydroxy-tamoxifen |
US20040137068A1 (en) | 2002-12-20 | 2004-07-15 | Rajiv Bhushan | Ophthalmic formulation for the prevention and treatment of adverse ocular conditions, particularly those associated with the aging eye |
WO2004060322A2 (fr) | 2003-01-02 | 2004-07-22 | Femmepharma Holding Company, Inc. | Preparations pharmaceutiques permettant le traitement de maladies et d'affections du sein |
CN100342856C (zh) | 2003-04-10 | 2007-10-17 | 上海医药工业研究院 | 达那唑半固体骨架制剂的组合物 |
GB2400554B (en) | 2003-04-16 | 2007-04-18 | George Margetts | Treatment of angiotensin II-induced cardiovascular disease |
WO2004103406A1 (fr) | 2003-05-26 | 2004-12-02 | Japan Science And Technology Agency | Composition therapeutique contre des maladies s'accompagnant d'une dimension ou d'une augmentation des plaquettes |
GB0313612D0 (en) | 2003-06-12 | 2003-07-16 | Novartis Ag | Organic compounds |
US20050101582A1 (en) | 2003-11-12 | 2005-05-12 | Allergan, Inc. | Compositions and methods for treating a posterior segment of an eye |
WO2005053660A2 (fr) | 2003-12-03 | 2005-06-16 | Lifecycle Pharma A/S | Compositions pharmaceutiques comprenant du danazol |
GB0329667D0 (en) | 2003-12-22 | 2004-01-28 | King S College London | Core 2 GlcNAc-T inhibitor |
US20050143362A1 (en) | 2003-12-31 | 2005-06-30 | Mclane Michael W. | Danazol for treatment of hypogonadism in the adult male |
US7442681B2 (en) | 2004-02-10 | 2008-10-28 | University Of Virginia Patent Foundation | Method of inhibiting vascular permeability |
US20050266005A1 (en) | 2004-02-27 | 2005-12-01 | Heavner George A | Methods and compositions for treating IL-3 related pathologies |
AU2005230811A1 (en) | 2004-04-06 | 2005-10-20 | Angiogenetics Sweden Ab | Angiogenesis-affecting compounds and methods of use thereof |
US20050244469A1 (en) | 2004-04-30 | 2005-11-03 | Allergan, Inc. | Extended therapeutic effect ocular implant treatments |
EP2803357B1 (fr) | 2004-06-25 | 2020-11-18 | The Johns-Hopkins University | Inhibiteurs d'angiogenèse |
GB2420281A (en) | 2004-11-22 | 2006-05-24 | Stegram Pharmaceuticals Ltd | Topical formulations for use in the treatment or prevention of dermatological conditions |
GB2421183A (en) | 2004-12-17 | 2006-06-21 | Stegram Pharmaceuticals Ltd | Topical formulations for use in the treatment or prevention of skin cancers |
WO2006082588A2 (fr) | 2005-02-07 | 2006-08-10 | Pharmalight Inc. | Procede et dispositif d'administration ophtalmique d'ingredients pharmaceutiquement actifs |
EP2500031A3 (fr) | 2005-02-24 | 2012-12-26 | Joslin Diabetes Center, Inc. | Compositions et procédés de traitement de la perméabilité vasculaire |
EP1861106A2 (fr) | 2005-03-02 | 2007-12-05 | Inc. Nascent Pharmaceutical | Polytherapie pour une application topique dans le traitement de degenerescence maculaire liee a l'age et d'hypertension oculaire |
SI1919290T1 (sl) | 2005-07-12 | 2014-05-30 | Ampio Pharmaceuticals, Inc. | Postopki in proizvodi za zdravljenje bolezni |
US8404643B2 (en) | 2005-12-22 | 2013-03-26 | Takeda Pharmaceutical Company Limited | Metastin derivatives and use thereof |
US20070173538A1 (en) | 2005-12-23 | 2007-07-26 | Alcon, Inc. | PHARMACEUTICAL FORMULATION FOR DELIVERY OF RECEPTOR TYROSINE KINASE INHIBITING (RTKi) COMPOUNDS TO THE EYE |
WO2007109363A2 (fr) | 2006-03-20 | 2007-09-27 | The Johns Hopkins University | Procédés et compositions permettant d'inhiber l'isoforme 1 de l'impdh |
US20080066739A1 (en) | 2006-09-20 | 2008-03-20 | Lemahieu Edward | Methods and systems of delivering medication via inhalation |
US8071779B2 (en) | 2006-12-18 | 2011-12-06 | Inspire Pharmaceuticals, Inc. | Cytoskeletal active rho kinase inhibitor compounds, composition and use |
CN101024082A (zh) | 2007-04-06 | 2007-08-29 | 张士东 | 一种全面预防和治疗心脑血管疾病复方药及其应用 |
ES2493641T3 (es) | 2007-06-28 | 2014-09-12 | Cydex Pharmaceuticals, Inc. | Administración nasal de soluciones acuosas de corticosteroides |
WO2009036108A1 (fr) | 2007-09-13 | 2009-03-19 | Children's Medical Center Corporation | Procédés et compositions pour inhiber une fuite vasculaire |
JP5767812B2 (ja) | 2007-12-06 | 2015-08-19 | バーグ リミテッド ライアビリティ カンパニー | 生物学的利用率が向上した吸入可能な組成物 |
JP5856843B2 (ja) * | 2008-05-27 | 2016-02-10 | アンピオ ファーマシューティカルズ,インコーポレイテッド | ジケトピペラジンを用いた医薬組成物 |
US20100323991A1 (en) * | 2009-06-22 | 2010-12-23 | Dmi Acquisition Corp. | Methods and products for treatment of diseases |
HUE028212T2 (en) * | 2009-06-22 | 2016-12-28 | Ampio Pharmaceuticals Inc | Procedure for treating diseases |
KR20140088542A (ko) | 2011-10-07 | 2014-07-10 | 앰피오 파마슈티컬스 인코퍼레이티드 | 비염의 치료 |
AU2013361338A1 (en) * | 2012-12-19 | 2015-08-06 | Ampio Pharmaceuticals, Inc. | Method for treatment of diseases |
-
2013
- 2013-12-19 AU AU2013361338A patent/AU2013361338A1/en not_active Abandoned
- 2013-12-19 EA EA201500752A patent/EA201500752A1/ru unknown
- 2013-12-19 US US14/134,249 patent/US9351979B2/en not_active Expired - Fee Related
- 2013-12-19 KR KR1020157019601A patent/KR20150105355A/ko not_active Application Discontinuation
- 2013-12-19 JP JP2015549680A patent/JP2016503794A/ja active Pending
- 2013-12-19 WO PCT/US2013/076421 patent/WO2014100352A1/fr active Application Filing
- 2013-12-19 SG SG11201504380SA patent/SG11201504380SA/en unknown
- 2013-12-19 MX MX2015007845A patent/MX2015007845A/es unknown
- 2013-12-19 CA CA2895340A patent/CA2895340A1/fr not_active Abandoned
- 2013-12-19 SG SG10201705044YA patent/SG10201705044YA/en unknown
- 2013-12-19 EP EP13866160.8A patent/EP2934546A4/fr not_active Withdrawn
- 2013-12-19 BR BR112015014261A patent/BR112015014261A8/pt not_active IP Right Cessation
- 2013-12-19 CN CN201380072209.2A patent/CN104968350A/zh active Pending
-
2015
- 2015-06-07 IL IL239273A patent/IL239273A0/en unknown
- 2015-07-14 PH PH12015501561A patent/PH12015501561A1/en unknown
-
2016
- 2016-04-19 HK HK16104469.6A patent/HK1216504A1/zh unknown
- 2016-04-27 US US15/139,938 patent/US10058562B2/en not_active Expired - Fee Related
Also Published As
Publication number | Publication date |
---|---|
US20160256475A1 (en) | 2016-09-08 |
US20140227347A1 (en) | 2014-08-14 |
IL239273A0 (en) | 2015-07-30 |
SG10201705044YA (en) | 2017-07-28 |
CN104968350A (zh) | 2015-10-07 |
HK1216504A1 (zh) | 2016-11-18 |
MX2015007845A (es) | 2015-09-29 |
PH12015501561A1 (en) | 2015-09-21 |
WO2014100352A1 (fr) | 2014-06-26 |
BR112015014261A8 (pt) | 2019-10-08 |
US9351979B2 (en) | 2016-05-31 |
EP2934546A4 (fr) | 2016-06-22 |
KR20150105355A (ko) | 2015-09-16 |
BR112015014261A2 (pt) | 2017-07-11 |
CA2895340A1 (fr) | 2014-06-26 |
EP2934546A1 (fr) | 2015-10-28 |
AU2013361338A1 (en) | 2015-08-06 |
US10058562B2 (en) | 2018-08-28 |
JP2016503794A (ja) | 2016-02-08 |
EA201500752A1 (ru) | 2016-05-31 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
EP2773754A4 (fr) | Méthode de traitement | |
GB201110095D0 (en) | Method of treatment | |
EP2717855A4 (fr) | Procédés de traitement | |
HK1199261A1 (en) | Methods for treatment of diseases | |
ZA201309557B (en) | Methods of treatment for retinal diseases | |
HK1215173A1 (zh) | 治療金黃色葡萄球菌相關疾病的方法 | |
EP2906295A4 (fr) | Méthodes de traitement de maladies oculaires | |
HK1203370A1 (en) | Method for treatment of labor arrest | |
HK1216504A1 (zh) | 疾病的治療方法 | |
IL238592A0 (en) | Methods for treating liver diseases | |
HK1199827A1 (en) | Method for treating gynecological diseases | |
EP2854784A4 (fr) | Méthode de traitement de maladies inflammatoires de la peau | |
EP2841060A4 (fr) | Méthode de prévention de maladies neurologiques | |
IL237229A0 (en) | Methods of treating cancer using lipoplatin | |
EP2791324A4 (fr) | Procédé de traitement | |
EP2911662A4 (fr) | Procédé de traitement d'une maladie | |
GB201221032D0 (en) | Method of treatment | |
GB201207894D0 (en) | Method of treatment | |
GB201111530D0 (en) | Method of treatment | |
GB201109509D0 (en) | Method of treatment | |
GB201109266D0 (en) | Method of treatment | |
GB201221118D0 (en) | Methods of treatment | |
GB201103044D0 (en) | Method of treatment | |
GB201216748D0 (en) | Methods of treatment | |
GB201216740D0 (en) | Methods of treatment |